{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:57:47Z","timestamp":1792612667408,"version":"4.5.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"vor","delay-in-days":382,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jacc.2021.11.007","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T15:42:44Z","timestamp":1641829364000},"page":"180-191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":112,"title":["Risk of Heart\u00a0Failure in Patients With Nonalcoholic Fatty Liver Disease"],"prefix":"10.1016","volume":"79","author":[{"given":"Alessandro","family":"Mantovani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Benfari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Bonapace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey G.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Targher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2021.11.007_bib1","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2021.11.007_bib2","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/ejhf.483","article-title":"Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review","volume":"18","author":"van Riet","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2021.11.007_bib3","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2021.11.007_bib4","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2021.11.007_bib5","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.cgh.2020.05.064","article-title":"Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States","volume":"19","author":"Younossi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jacc.2021.11.007_bib6","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S2468-1253(21)00308-3","article-title":"Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis","volume":"6","author":"Mantovani","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jacc.2021.11.007_bib7","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S2468-1253(21)00020-0","article-title":"Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach","volume":"6","author":"Targher","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jacc.2021.11.007_bib8","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41575-018-0010-0","article-title":"Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease","volume":"15","author":"Anstee","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jacc.2021.11.007_bib9","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.jacc.2018.11.050","article-title":"Nonalcoholic fatty liver disease and the heart: JACC state-of-the-art review","volume":"73","author":"Stahl","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.11.007_bib10","article-title":"Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications","author":"Byrne","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2021.11.007_bib11","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.11.007_bib12","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/eurheartj\/ehx721","article-title":"Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction","volume":"39","author":"Taqueti","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2021.11.007_bib13","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1148\/radiol.2019181793","article-title":"Association between nonalcoholic fatty liver disease at CT and coronary microvascular dysfunction at myocardial perfusion PET\/CT","volume":"291","author":"Vita","year":"2019","journal-title":"Radiology"},{"key":"10.1016\/j.jacc.2021.11.007_bib14","doi-asserted-by":"crossref","first-page":"E282","DOI":"10.1152\/ajpendo.00604.2005","article-title":"Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes","volume":"291","author":"Lautamaki","year":"2006","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.jacc.2021.11.007_bib15","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.jhep.2019.01.035","article-title":"The degree of hepatic steatosis associates with impaired cardiac and autonomic function","volume":"70","author":"Houghton","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jacc.2021.11.007_bib16","doi-asserted-by":"crossref","first-page":"e61803","DOI":"10.1371\/journal.pone.0061803","article-title":"Influence of non-alcoholic fatty liver disease on autonomic changes evaluated by the time domain, frequency domain, and symbolic dynamics of heart rate variability","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2021.11.007_bib17","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3389\/fphys.2020.00551","article-title":"Dysregulated neurovascular control underlies declining microvascular functionality in people with non-alcoholic fatty liver disease (NAFLD) at risk of liver fibrosis","volume":"11","author":"Clough","year":"2020","journal-title":"Front Physiol"},{"key":"10.1016\/j.jacc.2021.11.007_bib18","doi-asserted-by":"crossref","first-page":"3464","DOI":"10.1016\/j.numecd.2021.08.037","article-title":"Association between non-alcoholic fatty liver disease and impaired cardiac sympathetic\/parasympathetic balance in subjects with and without type 2 diabetes-The Cooperative Health Research in South Tyrol (CHRIS)-NAFLD sub-study","volume":"31","author":"Targher","year":"2021","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.jacc.2021.11.007_bib19","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1111\/liv.14461","article-title":"Nonalcoholic fatty liver disease is associated with increased risk of atrial fibrillation","volume":"40","author":"Cai","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jacc.2021.11.007_bib20","first-page":"1278","article-title":"Impact of nonalcoholic fatty liver disease on arrhythmia recurrence following atrial fibrillation ablation","volume":"6","author":"Donnellan","year":"2020","journal-title":"J\u00a0Am Coll Cardiol EP"},{"key":"10.1016\/j.jacc.2021.11.007_bib21","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0735-1097(99)00630-0","article-title":"Cardiac remodeling\u2013concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling","volume":"35","author":"Cohn","year":"2000","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.11.007_bib22","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s12020-019-02070-0","article-title":"Association between nonalcoholic fatty liver disease and cardiac function and structure-a meta-analysis","volume":"66","author":"Borges-Canha","year":"2019","journal-title":"Endocrine"},{"key":"10.1016\/j.jacc.2021.11.007_bib23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4254\/wjh.v9.i2.69","article-title":"From the liver to the heart: cardiac dysfunction in obese children with non-alcoholic fatty liver disease","volume":"9","author":"Di Sessa","year":"2017","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jacc.2021.11.007_bib24","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/oby.21879","article-title":"Nonalcoholic steatohepatitis is associated with cardiac remodeling and dysfunction","volume":"25","author":"Simon","year":"2017","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.jacc.2021.11.007_bib25","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.jhep.2017.11.023","article-title":"Association of non-alcoholic steatohepatitis with subclinical myocardial dysfunction in non-cirrhotic patients","volume":"68","author":"Lee","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jacc.2021.11.007_bib26","doi-asserted-by":"crossref","first-page":"e014279","DOI":"10.1161\/JAHA.119.014279","article-title":"Longitudinal association of non-alcoholic fatty liver disease with changes in myocardial structure and function: the CARDIA study","volume":"9","author":"VanWagner","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2021.11.007_bib27","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1161\/ATVBAHA.110.207340","article-title":"Serum gamma-glutamyl transferase and risk of heart failure in the community","volume":"30","author":"Dhingra","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2021.11.007_bib28","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1161\/ATVBAHA.111.240457","article-title":"Gamma-glutamyltransferase, hepatic enzymes, and risk of incident heart failure in older men","volume":"32","author":"Wannamethee","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2021.11.007_bib29","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1136\/heartjnl-2012-302972","article-title":"Serum gamma-glutamyltransferase and the risk of heart failure in men and women in Finland","volume":"99","author":"Wang","year":"2013","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2021.11.007_bib30","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s12872-020-01444-x","article-title":"Higher fatty liver index is associated with increased risk of new onset heart failure in healthy adults: a nationwide population-based study in Korea","volume":"20","author":"Roh","year":"2020","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.jacc.2021.11.007_bib31","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2020-322786","article-title":"Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort","author":"Simon","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jacc.2021.11.007_bib32","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.amjmed.2019.09.002","article-title":"Atrial fibrillation and heart failure with preserved ejection fraction in patients with nonalcoholic fatty liver disease","volume":"133","author":"Packer","year":"2020","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2021.11.007_bib33","doi-asserted-by":"crossref","first-page":"12440","DOI":"10.1038\/s41598-020-69013-y","article-title":"Prevalence and staging of non-alcoholic fatty liver disease among patients with heart failure with preserved ejection fraction","volume":"10","author":"Miller","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jacc.2021.11.007_bib34","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ijcard.2018.04.129","article-title":"Non-alcoholic fatty liver disease and increased risk of all-cause mortality in elderly patients admitted for acute heart failure","volume":"265","author":"Valbusa","year":"2018","journal-title":"Int J Cardiol"},{"issue":"5","key":"10.1016\/j.jacc.2021.11.007_bib35","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1002\/hep.32072","article-title":"Nonalcoholic fatty liver disease and cardiac remodeling risk: pathophysiological mechanisms and clinical implications","volume":"74","author":"Zhou","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2021.11.007_bib36","doi-asserted-by":"crossref","first-page":"046002","DOI":"10.1088\/1752-7163\/aacf12","article-title":"The characterisation of hepatic mitochondrial function in patients with non-alcoholic fatty liver disease (NAFLD) using the (13)C-ketoisocaproate breath test","volume":"12","author":"Afolabi","year":"2018","journal-title":"J\u00a0Breath Res"},{"key":"10.1016\/j.jacc.2021.11.007_bib37","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.omtn.2021.06.006","article-title":"Therapeutic potential and recent advances on targeting mitochondrial dynamics in cardiac hypertrophy: a concise review","volume":"25","author":"Aung","year":"2021","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.jacc.2021.11.007_bib38","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.3390\/ijms21124370","article-title":"MicroRNA and ROS crosstalk in cardiac and pulmonary diseases","volume":"21","author":"Climent","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jacc.2021.11.007_bib39","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nri1312","article-title":"NOX enzymes and the biology of reactive oxygen","volume":"4","author":"Lambeth","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jacc.2021.11.007_bib40","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.3748\/wjg.v23.i19.3396","article-title":"Renin angiotensin system in liver diseases: friend or foe?","volume":"23","author":"Sim\u00f5es","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jacc.2021.11.007_bib41","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1161\/CIRCRESAHA.116.307708","article-title":"Role of the ACE2\/Angiotensin 1-7 axis of the renin-angiotensin system in heart failure","volume":"118","author":"Patel","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2021.11.007_bib42","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/apt.15738","article-title":"Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis","volume":"51","author":"Carlsson","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.jacc.2021.11.007_bib43","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1053\/j.gastro.2020.12.023","article-title":"Exome-wide association study on alanine aminotransferase identifies sequence variants in the GPAM and APOE associated with fatty liver disease","volume":"160","author":"Jamialahmadi","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jacc.2021.11.007_bib44","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.pathol.2018.11.002","article-title":"Apolipoprotein E in lipoprotein metabolism, health and cardiovascular disease","volume":"51","author":"Marais","year":"2019","journal-title":"Pathology"},{"key":"10.1016\/j.jacc.2021.11.007_bib45","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3350\/cmh.2020.0129","article-title":"The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease","volume":"27","author":"Jennison","year":"2021","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jacc.2021.11.007_bib46","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/QCO.0000000000000759","article-title":"The impact of alteration in gut microbiome in the pathogenesis of nonalcoholic fatty liver disease","volume":"34","author":"Jacob","year":"2021","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.jacc.2021.11.007_bib47","doi-asserted-by":"crossref","first-page":"16","DOI":"10.21037\/jlpm.2020.01.01","article-title":"Impact of trimethylamine N-oxide (TMAO) metaorganismal pathway on cardiovascular disease","volume":"5","author":"Zhao","year":"2020","journal-title":"J\u00a0Lab Precis Med"},{"issue":"3","key":"10.1016\/j.jacc.2021.11.007_bib48","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1053\/j.gastro.2020.04.077","article-title":"Contribution of the intestinal microbiome and gut barrier to hepatic disorders","volume":"159","author":"Chopyk","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jacc.2021.11.007_bib49","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1146\/annurev-nutr-071816-064732","article-title":"Trimethylamine N-oxide, the microbiome, and heart and kidney disease","volume":"37","author":"Zeisel","year":"2017","journal-title":"Ann Rev Nutr"},{"key":"10.1016\/j.jacc.2021.11.007_bib50","doi-asserted-by":"crossref","first-page":"e020646","DOI":"10.1161\/JAHA.120.020646","article-title":"Longitudinal plasma measures of trimethylamine N-oxide and risk of atherosclerotic cardiovascular disease events in community-based older adults","volume":"10","author":"Lee","year":"2021","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2021.11.007_bib51","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1093\/eurheartj\/ehx342","article-title":"Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis","volume":"38","author":"Schiattarella","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2021.11.007_bib52","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.cmet.2017.04.001","article-title":"Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease","volume":"25","author":"Loomba","year":"2017","journal-title":"Cell Metab"},{"key":"10.1016\/j.jacc.2021.11.007_bib53","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/hep.26093","article-title":"Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH","volume":"57","author":"Zhu","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2021.11.007_bib54","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ijcard.2018.01.046","article-title":"Circulating interleukin-6 is a biomarker for coronary atherosclerosis in nonalcoholic fatty liver disease: results from the Multi-Ethnic Study of Atherosclerosis","volume":"259","author":"Simon","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2021.11.007_bib55","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1136\/gut.2010.214577","article-title":"Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor alpha expression","volume":"59","author":"Moschen","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.jacc.2021.11.007_bib56","first-page":"4196","article-title":"Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in\u00a0vivo","volume":"82","author":"Mohamed-Ali","year":"1997","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.jacc.2021.11.007_bib57","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijcard.2013.08.078","article-title":"Association of inflammatory factors with occurrence and recurrence of atrial fibrillation: a meta-analysis","volume":"169","author":"Wu","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2021.11.007_bib58","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.jacc.2021.04.003","article-title":"Pericardial fat and the risk of heart failure","volume":"77","author":"Kenchaiah","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.11.007_bib59","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/hep.29477","article-title":"A\u00a0randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis","volume":"67","author":"Friedman","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2021.11.007_bib60","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/hep.31108","article-title":"Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: final analysis of the phase 2b CENTAUR study","volume":"72","author":"Ratziu","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2021.11.007_bib61","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1016\/j.cgh.2019.04.061","article-title":"Daily aspirin use associated with reduced risk for fibrosis progression in patients with nonalcoholic fatty liver disease","volume":"17","author":"Simon","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jacc.2021.11.007_bib62","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.11.007_bib63","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise","volume":"67","author":"Romero-Gomez","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jacc.2021.11.007_bib64","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jacc.2021.11.007_bib65","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.soard.2017.09.534","article-title":"Bariatric surgery as a treatment for heart failure: review of the literature and potential mechanisms","volume":"14","author":"Kindel","year":"2018","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.jacc.2021.11.007_bib66","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s11695-015-1789-1","article-title":"Bariatric surgery provides a \u201cbridge to transplant\u201d for morbidly obese patients with advanced heart failure and may obviate the need for transplantation","volume":"26","author":"Lim","year":"2016","journal-title":"Obes Surg"},{"key":"10.1016\/j.jacc.2021.11.007_bib67","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41575-020-00366-5","article-title":"Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors","volume":"18","author":"Francque","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jacc.2021.11.007_bib68","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.diabet.2019.12.007","article-title":"Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: an updated systematic review of randomized controlled trials","volume":"46","author":"Mantovani","year":"2020","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.jacc.2021.11.007_bib69","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2021.11.007_bib70","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jacc.2021.11.007_bib71","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2021.11.007_bib72","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2021.11.007_bib73","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A\u00a0placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.jacc.2021.11.007_bib74","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3390\/metabo11020073","article-title":"Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials","volume":"11","author":"Mantovani","year":"2021","journal-title":"Metabolites"},{"key":"10.1016\/j.jacc.2021.11.007_bib75","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.jacc.2021.11.007_bib76","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/metabo11010022","article-title":"Sodium-glucose cotransporter-2 inhibitors for treatment of nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials","volume":"11","author":"Mantovani","year":"2020","journal-title":"Metabolites"},{"key":"10.1016\/j.jacc.2021.11.007_bib77","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications","volume":"398","author":"Brown","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2021.11.007_bib78","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ahj.2020.10.064","article-title":"Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes\u2014systematic review and meta-analysis of randomized placebo-controlled trials","volume":"232","author":"Salah","year":"2021","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2021.11.007_bib79","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.11.007_bib80","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.11.007_bib81","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N\u00a0Engl J Med"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109721081493?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109721081493?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T03:07:30Z","timestamp":1722308850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109721081493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":81,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0735109721081493"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2021.11.007","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of Heart\u00a0Failure in Patients With Nonalcoholic Fatty Liver Disease","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2021.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}